A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours

Completed · Phase 1

Conditions studied: Advanced or Metastatic Solid Tumours

In brief

This is an open-label, phase 1 study to determine the maximum tolerated dose (MTD) or appropriate target dose if MTD not reached to identify the recommended phase 2 dose of LOR-253 HCl in patients with advanced or metastatic solid tumours.

Key facts

Study ID

NCT01281592

Run by

Aptose Biosciences Inc.

People needed

36

Starts

2011-01-01

Expected to finish

2014-01-01

Last updated by the study team

2014-02-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female 18 years of age or older.
• Histologically confirmed diagnosis of solid tumour for which no effective therapy is available or that is unresponsive to conventional therapy.
• Meet laboratory parameter requirements at study entry.

You may not qualify if…

• Chemotherapy, radiotherapy, biologic therapy, immunotherapy or any other investigational drugs within 21 days of beginning study treatment with LOR-253 HCl.
• A hematologic malignancy.
• A history of brain or other central nervous system metastases.
• Have a presence of a significant infection.
• Clinically significant autoimmune disease.
• Uncontrolled intercurrent illness.
• With iron or copper overload syndromes.
• Pregnancy or breast feeding.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.